US FDA advisers vote against Otsuka's PTSD combination treatment

The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's 4578 drug when used in combination with Viatris' VTRS Zoloft for the treatment of adults with PTSD.